PubRank

Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 29020411)

Published in Eur Heart J on August 14, 2017

Authors

Brian A Ference1, Christopher P Cannon2, Ulf Landmesser3, Thomas F Lüscher4, Alberico L Catapano5, Kausik K Ray6

Author Affiliations

1: Division of Translational Research and Clinical Epidemiology, Division of Cardiovascular Medicine, Wayne State University School of Medicine, Detroit, MI, USA.
2: Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.
3: Department of Cardiology, Charite Universitäts Medizin Berlin, Campus Benjamin Franklin, Berlin, Germany.
4: Department of Cardiology, University Heart Center, University Hospital Zurich, Switzerland.
5: Department of Pharmacological and Biomolecular Sciences, MultiMedica Istituto di Ricovero e Cura a Carattere Scientifico, University of Milan, Via Balzaretti, 9, 20133 Milan, Italy.
6: Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, School of Public Health, Imperial College, London, UK.

Associated clinical trials:

Effects of Statin for Elderly Patients With Atherosclerotic Cardiovascular Disease | NCT04826354

Meta-analysis of Oat Fiber and Cardiovascular Risk Reduction. | NCT05171283

Articles by these authors ⇆

Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors. Eur Heart J (2017) 1.44

A report of quality improvement in the care of patients with acute coronary syndromes. Crit Pathw Cardiol (2011) 1.04

Critical pathways for management of patients with acute coronary syndromes: an assessment by the National Heart Attack Alert Program. Am Heart J (2002) 0.85

Individual quality improvement in acute coronary syndromes: a performance improvement initiative. Crit Pathw Cardiol (2009) 0.77

Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial. J Clin Lipidol (2014) 0.77

Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE study. J Cardiovasc Pharmacol Ther (2014) 0.76

Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes. J Am Heart Assoc (2017) 0.75

Platelet-related biomarkers and their response to inhibition with aspirin and p2y12-receptor antagonists in patients with acute coronary syndrome. J Thromb Thrombolysis (2017) 0.75

2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. Eur Heart J (2017) 0.75

Physician practice patterns in acute coronary syndromes: an initial report of an individual quality improvement program. Crit Pathw Cardiol (2010) 0.75

Amotosalen/UVA pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance. Haematologica (2017) 0.75